Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 3/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22403197 | 0.85 | MAPK1 (0.35) | METMAPK1SYKEGLN2 | |
| SCHEMBL25970784 | 0.82 | BRD4 (0.43) | BRD4MAPK1HASPIN | |
| SCHEMBL20504075 | 0.77 | BRD4 (0.46) | BRD4MAPK1 | |
| SCHEMBL25970869 | 0.77 | BRD4 (0.43) | BRD4MAPK1ACVR1HASPIN | |
| SCHEMBL25970672 | 0.77 | HTR3A (0.44) | BRD4METACVR1 | |
| SCHEMBL25970628 | 0.77 | BRD4 (0.44) | BRD4METHASPIN | |
| SCHEMBL25970829 | 0.76 | BRD4 (0.42) | BRD4METMAPK1ACVR1 | |
| SCHEMBL25970769 | 0.75 | BRD4 (0.43) | BRD4METMAPK1HASPIN | |
| SCHEMBL25970774 | 0.75 | BRD4 (0.43) | BRD4METMAPK1HASPIN | |
| SCHEMBL25970789 | 0.75 | BRD4 (0.43) | BRD4HASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | BRD4 1103/4885MET 1296/4885MAPK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.